PRESS RELEASE published on 04/11/2025 at 20:00, 1 year 6 months ago Publicatie jaarverslag - Jaarlijkse Algemene Vergadering Oxurion NV publice son rapport annuel 2024, convoque son assemblée annuelle d'actionnaires et se concentre sur les thérapies ophtalmologiques Rapport Annuel 2024 Oxurion NV Assemblée Annuelle Thérapies Ophtalmologiques Biofarmaceutique
BRIEF published on 04/04/2025 at 14:05, 1 year 7 months ago Report de l'Assemblée Générale d'Oxurion Assemblée Générale Biopharmaceutique Report Oxurion Thérapies Ophtalmologiques
BRIEF published on 04/04/2025 at 14:05, 1 year 7 months ago Oxurion General Meeting Postponed General Meeting Biopharmaceuticals Report Ophthalmic Therapies Oxurion
PRESS RELEASE published on 04/04/2025 at 14:00, 1 year 7 months ago Uitstel Gewone Algemene Vergadering Oxurion NV annonce le report de son Assemblée Générale des Actionnaires au 13 mai 2025 en raison de l'indisponibilité de ses états financiers Assemblée Générale États Financiers Report Risques Oxurion NV
PRESS RELEASE published on 04/04/2025 at 14:00, 1 year 7 months ago Postponement Annual Shareholders Meeting Oxurion NV postponed its Annual Shareholders Meeting to May 13, 2025, due to pending annual accounts. The biopharmaceutical company, focused on ophthalmic therapies, is based in Leuven, Belgium Biopharmaceutical Annual Shareholders Meeting Postponed Ophthalmic Therapies Oxurion NV
BRIEF published on 04/02/2025 at 18:05, 1 year 7 months ago Oxurion reçoit une notification de transparence de Atlas Special Opportunities II LLC Actions Transparence Atlas Special Opportunities Oxurion Biopharmacie
BRIEF published on 04/02/2025 at 18:05, 1 year 7 months ago Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC Actions Transparency Atlas Special Opportunities Oxurion Biopharmacy
PRESS RELEASE published on 04/02/2025 at 18:00, 1 year 7 months ago Oxurion ontvangt transparantiekennisgeving van Atlas Special Opportunities II LLC Oxurion NV ontvangt transparantiekennisgeving van Atlas Special Opportunities II LLC waaruit blijkt verkoop van aandelen onder drempel. Meer informatie op www.oxurion.com Transparantiekennisgeving Oxurion NV Oftalmologische Therapieën Biofarmaceutisch Bedrijf Atlas Special Opportunities II LLC
PRESS RELEASE published on 04/02/2025 at 18:00, 1 year 7 months ago Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC Oxurion NV, a biopharmaceutical company, received a transparency notification from Atlas Special Opportunities II, LLC regarding shareholding threshold crossing under Belgian legislation Transparency Notification Shareholding Threshold Oxurion NV Belgian Legislation Atlas Special Opportunities II LLC
BRIEF published on 03/27/2025 at 18:05, 1 year 7 months ago Oxurion reçoit une notification de transparence ajustée Actionnariat Notification De Transparence Oxurion Atlas Special Opportunities II Bourse De Bruxelles
Published on 11/10/2026 at 02:45, 4 hours 58 minutes ago Presentation to Zurich Precious Metals Summit
Published on 11/09/2026 at 23:10, 8 hours 33 minutes ago Ur-Energy Reports Third Quarter 2026 Results
Published on 11/09/2026 at 23:00, 8 hours 43 minutes ago LNG Energy Group Announces Issuance of Third Partial Revocation Order and Proposed Shares-for-Debt Settlement
Published on 11/09/2026 at 22:32, 9 hours 11 minutes ago Announces Extension for Closing of Private Placement of Convertible Promissory Notes
Published on 11/09/2026 at 22:15, 9 hours 28 minutes ago Goldcliff Announces Closing of the Second and Final Tranche of its "LIFE" Offering and Completion of Drilling at Kettle Valley
Published on 11/10/2026 at 07:38, 4 minutes ago Elmos Semiconductor SE continues profitable growth and strong cash generation in the third quarter of 2026
Published on 11/10/2026 at 07:30, 12 minutes ago Henkel posts very strong sales growth in the third quarter
Published on 11/10/2026 at 07:30, 13 minutes ago R. STAHL sales and profitability on track after nine months – Stabilization continues as planned – Forecast for 2026 confirmed
Published on 11/10/2026 at 07:30, 13 minutes ago Infineon closes FY 2026 with record quarter; expects revenue growth of more than 20 percent and a 5-percentage-point increase in profitability for FY 2027
Published on 11/10/2026 at 07:30, 13 minutes ago AUTO1 Group appoints Jörg Pietzner as Chief Financial Officer
Published on 11/10/2026 at 07:00, 43 minutes ago bioMérieux receives U.S. FDA 510(k) Clearance and IVDR CE marking for VITEK® PRO, its new automated ID/AST instrument to support the fight against antimicrobial resistance
Published on 11/10/2026 at 07:00, 43 minutes ago bioMérieux obtient l’autorisation 510(k) de la FDA américaine et le marquage CE selon l’IVDR pour VITEK® PRO, son nouvel instrument automatisé d’identification et d’antibiogramme contribuant à la lutte contre l’antibiorésistance
Published on 11/09/2026 at 18:30, 13 hours 13 minutes ago Air Liquide has successfully issued a CHF 390 million multi-tranche bond
Published on 11/09/2026 at 18:30, 13 hours 13 minutes ago Air Liquide a réalisé avec succès une émission obligataire multi-tranches de 390 millions de CHF
